Last updated 16 days ago
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
520 patients around the world
Available in Argentina, United States
Participants will be randomized 1:1 into two arms:
- Sacituzumab tirumotecan
- Pemetrexed plus Carboplatin
Participants will receive treatment until any of the criteria for discontinuation of
study intervention are met.
Merck Sharp & Dohme LLC
6Research sites
520Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Clínica Adventista Belgrano - CABA - Buenos Aires
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
Centro Privado de RMI Río Cuarto
Recruiting
SponsorMerck Sharp & Dohme LLC
Conditions
Non-small cell lung carcinomaLung cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06305754
